# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Jay Olson maintains Editas Medicine (NASDAQ:EDIT) with a Perform and maintains $12 price target.
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-fr...
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusi...
Evercore ISI Group analyst Liisa Bayko maintains Editas Medicine (NASDAQ:EDIT) with a In-Line and lowers the price target fr...
Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one o...
The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Ce...
Citigroup analyst Samantha Semenkow maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $16 ...